Gene signatures in U-BIOPRED severe asthma for molecular phenotyping and precision medicine: time for clinical use

Research output: Contribution to journalReview articlepeer-review

23 Downloads (Pure)


INTRODUCTION: The use and generation of gene signatures have been established as a method to define molecular endotypes in complex diseases such as severe asthma. Bioinformatic approaches have now been applied to large omics datasets to define the various co-existing inflammatory and cellular functional pathways driving or characterizing a particular molecular endotype.

AREAS COVERED: Molecular phenotypes and endotypes of Type 2 inflammatory pathways and also of non-Type 2 inflammatory pathways, such as IL-6 trans-signaling, IL-17 activation, and IL-22 activation, have been defined in the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes dataset. There has also been the identification of the role of mast cell activation and of macrophage dysfunction in various phenotypes of severe asthma.

EXPERT OPINION: Phenotyping on the basis of clinical treatable traits is not sufficient for understanding of mechanisms driving the disease in severe asthma. It is time to consider whether certain patients with severe asthma, such as those non-responsive to current therapies, including Type 2 biologics, would be better served using an approach of molecular endotyping using gene signatures for management purposes rather than the current sole reliance on blood eosinophil counts or exhaled nitric oxide measurements.

Original languageEnglish
Pages (from-to)965–971
Number of pages7
JournalExpert review of respiratory medicine
Issue number11
Early online date24-Nov-2023
Publication statusPublished - 2023

Cite this